The main purpose of this study is to evaluate the efficacy of the study drug Abemaciclib (LY2835219) and other therapies in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Your participation could last up to 18 months depending on how you and your tumor respond.
Participant must have a diagnosis of HR+, HER2- breast cancer
Participant must be able to swallow capsules
Participant must not be currently enrolled in a clinical trial involving an investigational product (IP) or non-approved use of a drug or device (other than the IP/device used in this study)
Participant must not have inflammatory breast cancer
Participant must not have received recent (within 28 days prior to randomization) live attenuated vaccines such as yellow fever vaccine
Participant must not have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
Participant must not have received an autologous or allogeneic stem-cell transplant
To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled. This website is not optimized for your browser, as configured.